Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR-Reference-Cited by-同舟云学术

Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR

Published:2020-03 Issue:3 Volume:31 Page:422-429
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Berthold F.,Faldum A.,Ernst A.,Boos J.,Dilloo D.,Eggert A.,Fischer M.,Frühwald M.,Henze G.,Klingebiel T.,Kratz C.,Kremens B.,Krug B.,Leuschner I.,Schmidt M.,Schmidt R.,Schumacher-Kuckelkorn R.,von Schweinitz D.,Schilling F.H.,Theissen J.,Volland R.,Hero B.,Simon T.

Funder

Deutsche Krebshilfe

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference27 articles.

1. Advances in risk classification and treatment strategies for neuroblastoma;Pinto;J Clin Oncol,2015

2. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: a study from the International Neuroblastoma Risk Group database;Morgenstern;Eur J Cancer,2016

3. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979-2015;Berthold;Paediatr Drugs,2017

4. The evidence for external beam radiotherapy in high-risk neuroblastoma of childhood: a systematic review;Arumugam;Clin Oncol (R Coll Radiol),2019

5. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1 year with residual local disease;Simon;Strahlenther Onkol,2006

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial;The Lancet Oncology;2024-07

2. Tolerability and toxicity of induction chemoimmunotherapy with dinutuximab beta in newly diagnosed patients with high-risk neuroblastoma;Pediatric Hematology/Oncology and Immunopathology;2024-04-17

3. Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review;Targeted Oncology;2024-02-24

4. Impaired Aortic Growth in Neuroblastoma Patients after Intensive Treatment;Journal of Pediatric Surgery;2023-12

5. Local MRI before and after Tumor Resection in Neuroblastoma: Impact of Residual Disease on Event Free Survival;Journal of Clinical Medicine;2023-11-24